Creative Touch Permanent Makeup and Aesthetics

Mesotherapy is an intradermal microinjection technique formalised by Michel Pistor in 1958, delivering small volumes of bioactive substances directly into the superficial dermis to achieve sustained local availability through a pharmacokinetic drug-sparing advantage. In aesthetic practice it typically delivers polycomponent cocktails combining non-cross-linked hyaluronic acid, B vitamins, vitamin C, amino acids, mineral salts, and antioxidants – designed to supply a comprehensive cellular nutrition environment rather than a single targeted receptor signal. The evidence base is moderate: hydration and skin quality benefits from established formulations such as NCTF135HA are clinically documented, though large-scale RCT evidence for structural collagen changes remains limited. Mesotherapy’s clinical value lies in biorevitalisation and cellular substrate provision, and it is most productive as a foundation or complementary layer within broader treatment protocols.

Mesotherapy is a minimally invasive injection technique in which small volumes of bioactive substances – 0.1 to 0.2 mL per injection point – are administered directly into the superficial or mid-dermis through a series of microinjections spaced 1 to 2 cm apart. The name derives from the mesoderm, the embryological middle tissue layer from which skin develops, and the technique was formalised as a clinical discipline by French physician Michel Pistor in 1958, drawing on earlier nineteenth-century observations that intradermal injection produced effects distinct from deeper routes. The first international evidence-based guidelines were published in 2025; a 2026 multi-society consensus confirmed 49 evidence-based recommendations with 92.6% expert agreement, marking mesotherapy’s formal transition from empirical practice to a standardised clinical framework. ^[3]

The Intradermal Pharmacokinetic Advantage

The core clinical rationale of mesotherapy is pharmacokinetic before it is pharmacological – and this is the part most explanations of the treatment overlook. Each microinjection creates a small wheal, or micro-depot, within the dermal tissue. Active substances are absorbed slowly from this depot into surrounding tissue rather than being immediately taken up into systemic circulation. Experimental data confirm that the area under the concentration-time curve (AUC) following intradermal delivery is greater than that achieved via intramuscular injection, indicating prolonged local tissue availability alongside a slower rate of systemic absorption. ^[3] This drug-sparing effect means smaller total doses achieve comparable local concentrations whilst reducing systemic exposure – the pharmacokinetic foundation that justifies delivering nutrients and actives this way rather than simply applying them topically.

The mechanism of effect extends beyond what is being delivered. The needle stimulus itself activates keratinocyte-mediated, glial, endorphin, and neuroimmune pathways independently of the injected substance, an interaction collectively described as mesodermal modulation. ^[3] Even saline injections produce measurable local effects through osmotic and physicochemical mechanisms, confirming that the delivery act contributes to the clinical outcome independently of the active ingredient profile. In practice, this makes the quality of the technique – injection depth, spacing, volume consistency – as clinically significant as the formulation.

What Aesthetic Mesotherapy Cocktails Contain

In aesthetic applications, mesotherapy is delivered as a polycomponent cocktail built on a cellular nutrition rationale: supply the full range of substrates and cofactors that dermal cells require for normal synthesis activity. The most extensively documented formulation is NCTF135HA (Filorga), CE-marked and in clinical use since 1978, which contains non-cross-linked hyaluronic acid, a full B-vitamin complex, vitamin C, amino acids, mineral salts, coenzymes, and nucleic acids. ^[4]

The key ingredients and their mechanistic roles:

• Non-cross-linked hyaluronic acid: Provides immediate dermal hydration and transient ECM support. Without cross-linking, it is degraded by endogenous hyaluronidase relatively quickly, producing measurable improvements in stratum corneum hydration and TEWL reduction whilst present – but without the structural persistence or mechanical fibroblast activation of cross-linked HA skin boosters. ^[4]

• Amino acids ( glycine, proline, hydroxyproline, lysine, arginine): Direct collagen synthesis precursors. Glycine and proline form the repeating G-X-Y triplet unit of the collagen triple helix; hydroxyproline is the hydroxylated form generated during intracellular procollagen maturation via the vitamin C-dependent prolyl hydroxylase reaction. Providing these locally addresses potential substrate limitations at the site of synthesis rather than relying solely on systemic supply.

• Vitamin C: An obligate hydroxylation cofactor for prolyl and lysyl hydroxylase – the enzymes that stabilise the procollagen triple helix – and a direct stimulator of procollagen mRNA expression in fibroblasts. Also suppresses UV-driven AP-1-mediated MMP-1 transcription, giving it simultaneous substrate-support and degradation-suppressing functions.

• Niacinamide ( vitamin B3): Upregulates ceramide synthesis via SPTLC2, supports sebum regulation, and promotes keratinocyte differentiation, making it relevant to barrier quality and epidermal function alongside fibroblast support. ^[4]

• Antioxidant complex (glutathione, CoQ10, resveratrol): Reduces the reactive oxygen species that drive AP-1-mediated MMP transcription, addressing the upstream trigger of collagen degradation rather than supplementing downstream consequences.

• B-vitamin complex (B1, B2, B6, B8, B12): Cellular metabolism cofactors supporting the energy pathways – the tricarboxylic acid cycle and electron transport chain – that fibroblasts and keratinocytes require for sustained synthesis activity.

In vitro studies on NCTF135HA demonstrated increased fibroblast proliferation alongside elevated mRNA expression of type I collagen, MMP-1, and TIMP-1 simultaneously, consistent with active matrix remodelling rather than unchecked degradation. ^[4]

What the Evidence Actually Shows

Mesotherapy occupies an unusual position in evidence-based aesthetics: its pharmacokinetic rationale is well-established; its specific aesthetic clinical evidence is genuinely mixed.

A 2012 histological study evaluated a three-month mesotherapy course in the periocular area using quantitative immunohistochemical morphometric analysis and found no statistically significant changes in collagen types I, III, or VII, newly synthesised collagen, total elastin, or tropoelastin. ^[1] This result was consistent with earlier controlled evaluations finding no photographically discernible differences. It cannot be dismissed as a methodology problem – immunohistochemical analysis is more sensitive and objective than satisfaction surveys or clinical photography.

On the other hand, a 10-year assessment of NCTF135HA documented a 43.3% reduction in crow’s feet wrinkle depth and a 24% increase in dermal density, with a randomised controlled trial within the programme finding significant hydration improvement at seven days post-final injection, measurably superior to a standard anti-ageing cream. ^[2] In vitro data from the same formulation supports its role in fibroblast activation and collagen remodelling balance.

The discrepancy likely reflects a real difference between formulations: the 2012 negative study used a multivitamin with HA solution; the positive long-term evidence comes from a comprehensively formulated polycomponent preparation. Formulation specificity matters here more than it does for treatments whose mechanism is receptor activation or thermal remodelling – you cannot extrapolate from one cocktail to another. The 2026 consensus from the Italian Society of Mesotherapy acknowledges explicitly that much evidence derives from smaller studies and expert consensus rather than large-scale RCTs, identifying this as a research priority. ^[3]

Clinical Pearl The negative histological study used a basic multivitamin + HA cocktail. The positive long-term outcomes come from NCTF135HA, a comprehensively formulated preparation developed and refined over decades. Product selection is not interchangeable in mesotherapy the way injection depth or technique largely is.

The honest synthesis: hydration, radiance, and skin quality improvements from well-formulated polycomponent cocktails are clinically plausible and modestly evidenced in controlled settings. Structural collagen synthesis at histological level comparable to targeted biostimulators is not what mesotherapy achieves – and claiming otherwise would misrepresent what the treatment actually does.

Mesotherapy and Skin Boosters: The Distinction That Matters

These two treatment categories are frequently conflated – both involve intradermal injection, both often include HA, both target skin quality. The differences are mechanistically meaningful enough to determine when each is the right choice.

The mechanistic distinction worth retaining: mesotherapy provides biological raw materials that cells need to function well. Skin boosters mechanically change the physical environment in which fibroblasts are operating, creating the structural tension that activates the TGF-β mechanoreception pathway. They are asking different things of the tissue – which is why they complement rather than substitute for each other.